Travere Therapeutics/TVTX

$6.37

-4.78%
-
1D1W1MYTD1YMAX

About Travere Therapeutics

Travere Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on identifying, developing, and delivering life-changing therapies to people living with rare kidney and metabolic diseases. Its product, FILSPARI (sparsentan), is indicated to reduce proteinuria in adults with primary IgAN at risk of rapid disease progression. Sparsentan is also in late-stage development for focal segmental glomerulosclerosis (FSGS). The Company’s Pegtibatinase is a novel investigational human enzyme replacement candidate being evaluated for the treatment of classical homocystinuria (HCU), which is a rare metabolic disorder. Its commercial products, Thiola and Thiola EC are for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones. It is also engaged in the identification of potential small molecule therapeutics for Alagille syndrome (ALGS).

Ticker

TVTX

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Eric Dube

Employees

380

Headquarters

San diego, United States

TVTX Metrics

BasicAdvanced
$509.17M
Market cap
-
P/E ratio
-$1.50
EPS
0.63
Beta
-
Dividend rate
$509.17M
0.63034
$22.75
$5.25
1.2M
3.467
3.414
187.871
187.871
-51.5%
-308.9%
-65.94%
3.506
2.511
5.284
32.69%
3.93%
-9.86%

What the Analysts think about TVTX

Analyst Ratings

Majority rating from 16 analysts.
Buy

Price Targets

Average projection from 15 analysts.
132.34% upside
High $21.00
Low $9.00
$6.37
Current price
$14.80
Average price target

TVTX Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
-200.22% profit margin
QuarterlyAnnual
Q4 23
QoQ growth
Revenue
$45M
21.62%
Net income
$-90.1M
-159.79%
Profit margin
-200.22%
-149.16%

TVTX Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 7.27%
QuarterlyAnnual
Q1 23
Q2 23
Q3 23
Q4 23
Q1 24
Actual
-$1.27
-$1.13
$1.97
-$1.18
-
Expected
-$1.17
-$1.14
-$0.14
-$1.27
-$0.97
Surprise
8.46%
-0.95%
-1,480.26%
-7.27%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

FAQs

What’s the current market cap for Travere Therapeutics stock?

Travere Therapeutics (TVTX) has a market cap of $509.17M as of April 13, 2024.

What is the P/E ratio for Travere Therapeutics stock?

The price to earnings (P/E) ratio for Travere Therapeutics (TVTX) stock is 0 as of April 13, 2024.

Does Travere Therapeutics stock pay dividends?

No, Travere Therapeutics (TVTX) stock does not pay dividends to its shareholders as of April 13, 2024.

When is the next Travere Therapeutics dividend payment date?

Travere Therapeutics (TVTX) stock does not pay dividends to its shareholders.

What is the beta indicator for Travere Therapeutics?

Travere Therapeutics (TVTX) has a beta rating of 0.63. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.

What is the Travere Therapeutics stock price target?

The target price for Travere Therapeutics (TVTX) stock is $14.8, which is 132.34% above the current price of $6.37. This is an average based on projections from 15 analysts, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell Travere Therapeutics stock

Buy or sell Travere Therapeutics stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing